A detailed history of Hanson & Doremus Investment Management transactions in Astrazeneca PLC stock. As of the latest transaction made, Hanson & Doremus Investment Management holds 14,621 shares of AZN stock, worth $979,753. This represents 0.18% of its overall portfolio holdings.

Number of Shares
14,621
Previous 14,983 2.42%
Holding current value
$979,753
Previous $1.17 Million 2.48%
% of portfolio
0.18%
Previous 0.2%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

SELL
$76.67 - $87.62 $27,754 - $31,718
-362 Reduced 2.42%
14,621 $1.14 Million
Q1 2024

Apr 22, 2024

SELL
$61.03 - $69.57 $13,853 - $15,792
-227 Reduced 1.49%
14,983 $1.02 Million
Q4 2023

Jan 25, 2024

SELL
$61.89 - $69.28 $14,729 - $16,488
-238 Reduced 1.54%
15,210 $1.02 Million
Q3 2023

Oct 24, 2023

SELL
$64.85 - $71.7 $38,585 - $42,661
-595 Reduced 3.71%
15,448 $1.05 Million
Q2 2023

Jul 18, 2023

SELL
$69.91 - $75.81 $26,425 - $28,656
-378 Reduced 2.3%
16,043 $1.15 Million
Q1 2023

Apr 18, 2023

SELL
$63.15 - $71.6 $18,439 - $20,907
-292 Reduced 1.75%
16,421 $1.14 Million
Q4 2022

Jan 18, 2023

SELL
$54.21 - $70.44 $43,693 - $56,774
-806 Reduced 4.6%
16,713 $1.13 Million
Q3 2022

Oct 20, 2022

SELL
$53.02 - $135.75 $30,062 - $76,970
-567 Reduced 3.14%
17,519 $961,000
Q2 2022

Jul 19, 2022

SELL
$59.26 - $71.14 $170,609 - $204,812
-2,879 Reduced 13.73%
18,086 $1.2 Million
Q1 2022

Apr 22, 2022

SELL
$55.72 - $67.12 $63,632 - $76,651
-1,142 Reduced 5.17%
20,965 $1.39 Million
Q4 2021

Jan 20, 2022

SELL
$54.02 - $63.83 $8,319 - $9,829
-154 Reduced 0.69%
22,107 $1.29 Million
Q3 2021

Oct 21, 2021

SELL
$55.56 - $60.79 $128,843 - $140,972
-2,319 Reduced 9.43%
22,261 $1.34 Million
Q2 2021

Jul 22, 2021

BUY
$48.42 - $60.18 $21,256 - $26,419
439 Added 1.82%
24,580 $1.35 Million
Q1 2021

May 03, 2021

BUY
$47.16 - $54.44 $943 - $1,088
20 Added 0.08%
24,141 $1.2 Million
Q4 2020

Feb 01, 2021

SELL
$48.52 - $58.02 $22,270 - $26,631
-459 Reduced 1.87%
24,121 $1.21 Million
Q3 2020

Oct 19, 2020

SELL
$53.07 - $61.1 $74,191 - $85,417
-1,398 Reduced 5.38%
24,580 $1.35 Million
Q2 2020

Jul 17, 2020

SELL
$43.1 - $55.31 $46,461 - $59,624
-1,078 Reduced 3.98%
25,978 $1.37 Million
Q1 2020

Apr 24, 2020

SELL
$37.79 - $51.33 $76,600 - $104,045
-2,027 Reduced 6.97%
27,056 $1.21 Million
Q4 2019

Jan 16, 2020

SELL
$42.46 - $50.46 $30,358 - $36,078
-715 Reduced 2.4%
29,083 $1.45 Million
Q3 2019

Oct 18, 2019

SELL
$40.12 - $45.47 $59,377 - $67,295
-1,480 Reduced 4.73%
29,798 $1.33 Million
Q2 2019

Jul 18, 2019

SELL
$37.28 - $41.68 $35,416 - $39,596
-950 Reduced 2.95%
31,278 $1.29 Million
Q1 2019

Apr 23, 2019

BUY
$35.49 - $43.02 $3,371 - $4,086
95 Added 0.3%
32,228 $0
Q4 2018

Jan 31, 2019

SELL
$36.86 - $41.49 $81,571 - $91,817
-2,213 Reduced 6.44%
32,133 $1.22 Million
Q3 2018

Oct 24, 2018

SELL
$34.76 - $39.72 $3,997 - $4,567
-115 Reduced 0.33%
34,346 $0
Q2 2018

Aug 08, 2018

SELL
$34.55 - $37.05 $47,333 - $50,758
-1,370 Reduced 3.82%
34,461 $1.21 Million
Q1 2018

May 10, 2018

BUY
$32.97 - $36.63 $94,656 - $105,164
2,871 Added 8.71%
35,831 $1.25 Million
Q3 2017

Oct 26, 2017

BUY
$28.96 - $34.0 $954,521 - $1.12 Million
32,960
32,960 $0

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $208B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Hanson & Doremus Investment Management Portfolio

Follow Hanson & Doremus Investment Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hanson & Doremus Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Hanson & Doremus Investment Management with notifications on news.